Dr Mike Stierstorfer, MD, FAAD:
Treatment testimonial video
Transcript
My name is Dr Mike Stierstorfer. I’m a dermatologist in Philadelphia, Pennsylvania. I see a lot of patients for their annual or semi-annual skin cancer screening who have a lot of actinic keratoses. This is my experience.
I started prescribing KLISYRI® after learning of its effectiveness in clearing actinic keratoses and its short 5-day course of therapy. I was also intrigued by the drug’s tolerability profile and that most local skin reactions were mild to moderate in clinical trials.
I like to prescribe KLISYRI® for patients with many actinic keratoses in need of field therapy, but also for patients with just a few actinic keratoses. It’s also good for patients who want to avoid more invasive treatments like cryotherapy. Patients have been very happy with KLISYRI® treatment. They especially like its short 5-day course of therapy and its ready accessibility through specialty pharmacies.
If you haven’t yet used KLISYRI®, I’d recommend you give it a try. Maybe ask for some samples and try them first. Try it in any situation where you would have previously chosen a different type of field therapy. I’d especially encourage you to use it in those patients that we all have who vow to never go through another course of field therapy after a bad experience. Just as my patients have uniformly thanked me for prescribing KLISYRI® for them, your patients may thank you as well.
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
References: 1. Data on file. 2019. KX01-AK-004. 2. Data on file. 2019. KX01-AK-003. 3. KLISYRI®. Prescribing information. Almirall, LLC.
KLISYRI® is a registered trademark of Almirall, LLC.
© Copyright 2005-2022
All Rights Reserved.
Almirall, LLC. 101 Lindenwood Drive, Ste 400, Malvern, PA 19355
US-TIRBA-2100190 05/2022
IMPORTANT SAFETY INFORMATION
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com